During the first quarter 2014, Biotechnology companies attracted
"Life sciences and biotechnology investments are off to the strongest start of the year since the recession," said
While first quarter 2014 overall Life Sciences deal value and volume decreased 10 percent and 28 percent respectively compared to the fourth quarter 2013, average Life Sciences deal size rose 15 percent to
"There is a lot of competition for capital and venture funds are being selective in their investments, which explains why life sciences underperformed total venture capital investments," Vlahos continued. "There is still a lot of interest in the space but investors recognize that these deals have longer durations and higher capital requirements. The increase in average deal value and early stage investments tells us that investors have a growing appetite for risk and are placing bigger bets on a smaller number of life sciences companies in hopes of generating outsized returns."
Keywords for this news article include: Biotechnology, PwC Us, Finance and Investment, Investment and Finance.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Criminal Investigation Opened Into James Foley's Death
- The Hip New Career? Farming
- McDonald's Names Another U.S. President
- Student Startup Develops Date-rape Detector
- Sahara Casino Rises Anew as SLS Las Vegas
- U.S. Supporters of Islamic State Get Close Scrutiny
- Chinese Coal Gas Boom Poses Climate Risks
- Job Market Shifts Complicate Yellen's Rate Decision
- Dems Losing Fear of Obamacare
- Is Diversity in the Eye of the Beholder?